By 2030, Malta, Hungary, and the United Kingdom were projected to have the highest prevalence of obesity in their populations among men in Europe. Across the whole of Europe, approximately ** percent of men were forecast to be classified as obese in 2030.

This statistis displays the growth in obesity rates in selected European countries in 1975 and 2014. The obesity rate in Ireland grew from *** percent in 1975 to **** percent in 2014.

By 2030, Turkey was projected to have the highest prevalence of obesity among women at ** percent, followed by the United Kingdom at ** percent. Across the whole of Europe, almost ** percent of women were forecast to have a BMI classified as obese by 2030.

Introduction: Using data from the TackSHS survey, we aim to provide updated estimates on the prevalence and determinants of overweight and obesity in Europe. Methods: A face-to-face survey was conducted in 2017-2018 in 12 European countries (Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania, and Spain). Overall, 10,810 participants, representative in each country of the general adult population, provided information on self-reported height and weight. Results: Almost half of participants (48.1%; 95% confidence interval, CI: 47.2-49.1) reported to be overweight or obese (54.1% in men and 42.5% in women), and 12.6% (95% CI: 12.0-13.2) obese (11.3% in men and 13.8% in women). Obesity prevalence was lowest in Italy (7.5%) and France (8.8%), and highest in Greece (19.7%) and Romania (21.1%). Multilevel logistic random-effects analyses showed that prevalence of obesity was related with higher age and lower level of education and socioeconomic status. As compared to northern European countries, Western and Southern European ones showed a significantly lower obesity prevalence. When compared to a companion study conducted in 2010, Eastern and Northern European countries showed an increased trend in obesity prevalence. Conversely, countries with the lowest obesity prevalence (less than 10%), such as Italy and France, showed a decreased trend. Conclusions: Despite a large heterogeneity across countries, overweight and obesity prevalence estimates in Europe are alarming, with most of the countries reporting obesity prevalence approaching 20% or more, particularly in Eastern and Northern Europe. Since 2010, obesity prevalence increased in most of these countries.

By 2025, the prevalence of obese women in the United Kingdom is projected to be at ** percent, this would be the highest obesity prevalence in women compared to EU countries. Ireland with **** percent was forecast to have the second highest prevalence of obese women in Europe, followed by Malta at ** percent.

Introduction: Obesity constitutes a major public health problem in Europe, but how the obesity epidemic in European countries will evolve remains unknown. Most previous obesity projections considered the short-term future only, focused on single non-European countries, and projected ongoing increases foremost. We comparatively project obesity prevalence into the long-term future for 18 European countries and the USA. Data: We used national age-specific (20–84 years) and sex-specific obesity prevalence estimates (1975–2016) from the NCD Risk Factor Collaboration (NCD-RisC) 2017 study, which are based on available measured height and weight data, supplemented with estimates from a Bayesian hierarchical model. Methods: We projected age- and sex-specific obesity prevalence up to the year 2100 by integrating the notion of a wave-shaped obesity epidemic into conventional age-period projections. Results: In 1990–2016, the increasing trends in obesity prevalence were decelerating. Obesity is expected to reach maximum levels between 2030 and 2052 among men, and between 2026 and 2054 among women. The maximum levels will likely be reached first in The Netherlands, USA, and UK, and last in Switzerland; and are expected to be highest in the USA and UK, and lowest in The Netherlands for men and Denmark for women. In 2060, obesity prevalence is expected to be lowest among Dutch men and highest among Swiss men. The projected age-specific obesity prevalence levels have an inverse U-shape, peaking at around the age of 60–69 years. Discussion: Applying our novel approach to the NCD-RisC 2017 data, obesity prevalence is expected to reach maximum levels between 2026 and 2054, with the USA and UK reaching the highest maximum levels first, followed by other European countries.

Historical dataset showing European Union obesity rate by year from N/A to N/A.

By 2025, the prevalence of obese children in Greece is projected to reach **** percent, this would be the highest childhood obesity prevalence across all countries in the EU and the UK. Hungary with **** percent was forecast to have the second-highest prevalence of childhood obesity in Europe, followed by Croatia at **** percent.

IntroductionOvereating is one of the main drivers of obesity due to the accumulation of excess body fat (EBF). This issue not only impacts human health but also depletes the planet’s environmental resources through the production of excess food. Thus, the Metabolic Food Waste (MFW) index was developed to measure the food wasted due to EBF accumulation, associated greenhouse gas (GHG) emissions, and the water and land resources used in its production.MethodsThe present study aims to evaluate and compare the MFW and ecological footprints of some Mediterranean countries (MC) and North European countries (NEC). The MFW for six Mediterranean and North European countries (NEC) was calculated using the following: (i) EBF: This is defined as the difference between ideal and actual body weight in overweight and obese adults, with data sourced from the FAOSTAT and WHO databases; (ii) Food waste: This includes the food wasted due to EBF accumulation and energy intake from major food categories. Data for food waste were obtained from the FAO Food Balance Sheets; and (iii) Environmental Impact: This encompasses GHG emissions, water consumption, and land use associated with EBF by different foods. Data were obtained from the WWF Virtual Shopping Cart and the Barilla Centre for Food and Nutrition. Data were analyzed for the total population and standardized per 100,000 citizens.ResultsThe results showed that NEC had the highest rates of obesity, while MC recorded slightly higher rates of individuals classified as overweight. Overall, higher EBF values for 100,000 citizens, including both obese and overweight individuals, were found in NEC compared to MC, with smaller population countries predominantly contributing to these trends. Data on MFW and ecological footprints showed that, regardless of the country, the impact of obesity is two to three times greater than that of being overweight. The highest values of MFW and ecological footprints were found in MC, both in the total and among overweight/obese populations.DiscussionThe present study highlights the harmful role of the overeating as on human health as on the resource exploitations of the Earth. In particular, both MC and NEC showed similar alarming data about overeating and, consequently, negative impact on EBF and ecological footprints, suggesting that residence in countries close or far from Mediterranean basin is not a proxy of adherence to healthy dietary patterns. For this reason, informative campaigns should be developed to improve the knowledge on conscious dietary choices for human and planet healthiness.

This statistic displays the obesity prevalence in selected European countries by 2025. Great Britain is set to be the most obese nation in Europe by 2025 with an obesity prevalence of **** percent, followed closely by Ireland and Lithuania with an expected prevalence rate of ***** percent respectively.

The size of the Weight Loss Surgery Market in Europe market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 15.00% during the forecast period. Recent developments include: In June 2022, Rhythm Pharmaceuticals, Inc. announced that IMCIVREE is available to patients in Germany.The European Commission granted IMCIVREE marketing authorization for the treatment of obesity and the management of hunger in adults and children aged 6 and older with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1 deficiency or biallelic leptin receptor deficiency., In June 2022, European Medicines Agency (EMA) safety committee Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the withdrawal of European Union (EU) marketing authorisations for amfepramone obesity medicines.. Key drivers for this market are: Increase in Obese Population, Prevalence of Diabetes and Heart Diseases; Government Initiatives to Curb Obesity; Insurance Coverage of Surgeries. Potential restraints include: Lack of Knowledge and Awareness in the Region, High Cost of Surgery. Notable trends are: Gastric Balloons Segment is Expected to Witness the Highest CAGR in the Market Over the Forecast Period.

The analyses of geographic variations in the prevalence of major chronic conditions, such as overweight and obesity, are an important public health tool to identify “hot spots” and inform allocation of funding for policy and health promotion campaigns, yet rarely performed. Here we aimed at exploring, for the first time in Luxembourg, potential geographic patterns in overweight/obesity prevalence in the country, adjusted for several demographic, socioeconomic, behavioural and health status characteristics. Data came from 720 men and 764 women, 25–64 years old, who participated in the European Health Examination Survey in Luxembourg (2013–2015). To investigate the geographical variation, geo-additive semi-parametric mixed model and Bayesian modelisations based on Markov Chain Monte Carlo techniques for inference were performed. Large disparities in the prevalence of overweight and obesity were found between municipalities, with the highest rates of obesity found in 3 municipalities located in the South-West of the country. Bayesian approach also underlined a nonlinear effect of age on overweight and obesity in both genders (significant in men) and highlighted the following risk factors: 1. country of birth for overweight in men born in a non-European country (Posterior Odds Ratio (POR): 3.24 [1.61–8.69]) and women born in Portugal (POR: 2.44 [1.25–4.43]), 2. low educational level (secondary or below) for overweight (POR: 1.66 (1.06–2.72)] and obesity (POR:2.09 [1.05–3.65]) in men, 3. single marital status for obesity in women (POR: 2.20 [1.24–3.91]), 4.fair (men: POR: 3.19 [1.58–6.79], women: POR: 2.24 [1.33–3.73]) to very bad health perception (men: POR: 15.01 [2.16–98.09]) for obesity, 5. sleeping more than 6 hours for obesity in unemployed men (POR: 3.66 [2.02–8.03]). Protective factors highlighted were: 1. single marital status against overweight (POR: [0.60 (0.38–0.96)]) and obesity (POR: 0.39 [0.16–0.84]) in men, 2. the fact to be widowed against overweight in women (POR: [0.30 (0.07–0.86)], as well as a non European country of birth (POR: 0.49 [0.19–0.98]), tertiary level of education (POR: 0.34 [0.18–0.64]), moderate alcohol consumption (POR: 0.54 [0.36–0.90]) and aerobic physical activity practice (POR: 0.44 [0.27–0.77]) against obesity in women. A double burden of environmental exposure due to historic mining and industrial activities and past economic vulnaribility in the South-West of the country may have participated to the higher prevalence of obesity found in this region. Other demographic, socioeconomic, behavioural and health status covariates could have been involved as well.

As of 2024, approximately ** percent of men and ** percent of women in Romania considered themselves overweight or obese. Across the European countries featured, being overweight or obese was more prevalent among males.

Background: In Europe, although the prevalence of childhood obesity seems to be plateauing in some countries, progress on tackling this important public health issue remains slow and inconsistent. Breastfeeding has been described as a protective factor, and the more exclusively and the longer children are breastfed, the greater their protection from obesity. Birth weight has been shown to have a positive association with later risk for obesity. Objectives: It was the aim of this paper to investigate the association of early-life factors, namely breastfeeding, exclusive breastfeeding and birth weight, with obesity among children. Method: Data from 22 participating countries in the WHO European COSI study (round 4: 2015/2017) were collected using cross-sectional, nationally representative samples of 6- to 9-year-olds (n = 100,583). The children’s standardized weight and height measurements followed a common WHO protocol. Information on the children’s birth weight and breastfeeding practice and duration was collected through a family record form. A multivariate multilevel logistic regression analysis regarding breastfeeding practice (both general and exclusive) and characteristics at birth was performed. Results: The highest prevalence rates of obesity were observed in Spain (17.7%), Malta (17.2%) and Italy (16.8%). A wide between-country disparity in breastfeeding prevalence was found. Tajikistan had the highest percentage of children that were breastfed for ≥6 months (94.4%) and exclusively breastfed for ≥6 months (73.3%). In France, Ireland and Malta, only around 1 in 4 children was breastfed for ≥6 months. Italy and Malta showed the highest prevalence of obesity among children who have never been breastfed (21.2%), followed by Spain (21.0%). The pooled analysis showed that, compared to children who were breastfed for at least 6 months, the odds of being obese were higher among children never breastfed or breastfed for a shorter period, both in case of general (adjusted odds ratio [adjOR] [95% CI] 1.22 [1.16–1.28] and 1.12 [1.07–1.16], respectively) and exclusive breastfeeding (adjOR [95% CI] 1.25 [1.17–1.36] and 1.05 [0.99–1.12], respectively). Higher birth weight was associated with a higher risk of being overweight, which was reported in 11 out of the 22 countries. Bulgaria, Croatia, France, Italy, Poland and Romania showed that children who were preterm at birth had higher odds of being obese, compared to children who were full-term babies. Conclusion: The present work confirms the beneficial effect of breastfeeding against obesity, which was highly increased if children had never been breastfed or had been breastfed for a shorter period. Nevertheless, adoption of exclusive breastfeeding is below global recommendations and far from the target endorsed by the WHO Member States at the World Health Assembly Global Targets for Nutrition of increasing the prevalence of exclusive breastfeeding in the first 6 months up to at least 50% by 2025.

This statistic displays the share of children between *** and nine years who are obese in Europe from 2015 to 2017, by gender . In this period, **** percent of girls and boys in Denmark were obese.

The European weight loss surgery market is experiencing robust growth, driven by rising obesity rates, increasing awareness of bariatric procedures, and advancements in minimally invasive surgical techniques. The market, valued at approximately €X million in 2025 (assuming a logical extrapolation based on the provided CAGR of 15% and the unspecified market size "XX" – a precise figure requires the missing "XX" value), is projected to reach €Y million by 2033. This significant expansion is fueled by several key factors. The increasing prevalence of obesity and related comorbidities like type 2 diabetes and cardiovascular disease is creating a substantial demand for effective weight loss solutions. Furthermore, technological advancements in devices such as suturing devices, stapling devices, and implantable gastric bands are leading to safer, less invasive procedures with improved patient outcomes, driving market penetration. The segment of assisting devices, encompassing suturing, closure, and stapling devices, is expected to dominate the market due to its widespread use in various bariatric surgeries. However, the growth is also influenced by factors like high procedure costs, potential complications associated with surgery, and varying reimbursement policies across European countries. Growth across the major European markets – Germany, the United Kingdom, France, Italy, and Spain – will contribute significantly to the overall market expansion. However, disparities in healthcare infrastructure and insurance coverage may lead to regional variations in adoption rates. The competitive landscape includes established players like Allergan, Ethicon, and Covidien, as well as emerging companies focusing on innovative technologies. These companies are constantly investing in research and development to introduce advanced devices and improve surgical techniques, further propelling the market's growth. While regulatory hurdles and potential risks associated with weight loss surgery present challenges, the overall outlook for the European weight loss surgery market remains positive, indicating substantial growth opportunities over the forecast period. (Note: 'X' and 'Y' represent calculated values derived from the 15% CAGR and the missing base market size. To obtain precise figures, the missing market size data is required). Recent developments include: In June 2022, Rhythm Pharmaceuticals, Inc. announced that IMCIVREE is available to patients in Germany.The European Commission granted IMCIVREE marketing authorization for the treatment of obesity and the management of hunger in adults and children aged 6 and older with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1 deficiency or biallelic leptin receptor deficiency., In June 2022, European Medicines Agency (EMA) safety committee Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the withdrawal of European Union (EU) marketing authorisations for amfepramone obesity medicines.. Key drivers for this market are: Increase in Obese Population, Prevalence of Diabetes and Heart Diseases; Government Initiatives to Curb Obesity; Insurance Coverage of Surgeries. Potential restraints include: Increase in Obese Population, Prevalence of Diabetes and Heart Diseases; Government Initiatives to Curb Obesity; Insurance Coverage of Surgeries. Notable trends are: Gastric Balloons Segment is Expected to Witness the Highest CAGR in the Market Over the Forecast Period.

The market is expected to attain USD 3.7 Billion by 2035, recording a CGAR of 4.9% over the forecast period, credible to be valued at USD 2.3 Billion in 2025.

Country Wise Analysis

Competitive Outlook

By 2030, Hungary, Turkey, and Croatia were projected to have the highest prevalence of childhood obesity (between 5 and 19 years of age) across Europe at ** percent. Across the whole of Europe, it was projected that just over ** percent of children aged between five and nine years of age would be classed as obese by 2030.

In recent years, concerted political efforts have been made at the national and European Union (EU) level to promote the consumption of healthy foods. The European Commission (EC) expressed the need for a harmonized and mandatory front-of-pack nutrition labeling (FOPL) system at the EU level. The EC will adopt the proposal by the end of 2022. Our research work aims to understand the public discourse on FOPL in the EU via Twitter, by analyzing tweet content, sentiment, and mapping network characteristics. Tweet search and data collection were performed using the Twitter application programming interface (API), with no time or language restrictions. The content was coded with the QRS Nvivo software package and analyzed thematically. Automatic sentiment analysis was performed with QSR Nvivo, and network analysis was performed with Gephi 0.9.2. A total of 4,073 tweets were posted, mostly from the UK, Spain, and France. Themes that have emerged from the discussion on Twitter include the types of food labeling, food industry, healthy vs. unhealthy foods in the context of food labeling, EU regulation, political conflicts, and science and education. Nutri-Score dominated the discussion on Twitter. General topics were perceived negatively by Twitter users with more positive sentiments toward the food industry, while negative sentiments were observed toward the discourse of political conflicts. The network analysis showed that a centralized communication was hardly existed between countries. Our results reveal that the discussion of FOPL on Twitter is limited to a very limited group of people, and it seems necessary to inform a wide range of consumers about existing and upcoming FOPL schemes. Educational programs should empower consumers to understand what a healthy diet is and how it relates to FOPL, regardless of the existing labeling system.

Introduction: The obesity epidemic has become one of the most important public health issues of modern times. Impaired insulin sensitivity seems to be the cornerstone of multiple obesity related comorbidities. However, there is no accepted definition of impaired insulin sensitivity. Objective: We hypothesize that assessment of insulin resistance differs between centers. Methods: The ESPE Obesity Working Group (ESPE ObWG) Scientific Committee developed a questionnaire with a focus on the routine practices of assessment of hyperinsulinemia and insulin resistance, which was distributed through Google Docs platform to the clinicians and researchers from the current ESPE ObWG database (n = 73). Sixty-one complete responses (84% response rate) from clinicians and researchers were analyzed: 32 from European Union (EU) centers (representatives of 14 countries) and 29 from Non-EU centers (representatives from 10 countries). Standard statistics were used for the data analysis. Results: The majority of respondents considered insulin resistance (IR) as a clinical tool (85.2%) rather than a research instrument. For the purpose of IR assessment EU specialists prefer analysis of the oral glucose tolerance test (OGTT) results, whereas non-EU ones mainly use Homeostatic Model Assessment of Insulin Resistance (HOMA-IR; p = 0.032). There was no exact cutoff for the HOMA-IR in either EU or non-EU centers. A variety of OGTT time points and substances measured per local protocol were reported. Clinicians normally analyzed blood glucose (88.52% of centers) and insulin (67.21%, mainly in EU centers, p = 0.0051). Furthermore, most participants (70.5%) considered OGTT insulin levels as a more sensitive parameter of IR than glucose. Meanwhile, approximately two-thirds (63.9%) of the centers did not use any cutoffs for the insulin response to the glucose load. Conclusions: Since there is no standard for the IR evaluation and uniform accepted indication of performing, an OGTT the assessment of insulin sensitivity varies between EU and non-EU centers. A widely accepted standardized protocol is needed to allow comparison between centers.